Innocare releases 2023 results and business highlights

Beijing--(business wire)--innocare pharma (hkex: 09969; sse: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2023 annual results as of 31 december 2023. financial highlights revenue increased by 18.1% to rmb738.5 million in 2023, including rmb670.7 million from orelabrutinib, an increase of 18.5%, mainly due to the continuous and rapid ramp-up of orelabrutinib sales. gross profit increased by 26.6% to rmb610.1 million in 2023, with a.
CR Ratings Summary
CR Quant Ranking